Syndeio: Tuning synaptic function via predictive pharmacology

Syndeio’s ‘function-first’ precision pharmacology platform aims to treat psychiatric symptoms by dialing in the right level of synaptic plasticity, enhancing synaptic function without tipping the system into desensitization. The company, which launched in May, is a roll-up of two biotechs that bring together a preclinical screening platform, a pipeline that includes two clinical candidates, and $90 million in venture funding. 

Previous attempts to target synapses have sought to achieve peak modulation within an 18-24 hour plasma half-life to enable daily oral dosing. However, the problem with frequent dosing is that synapses can quickly become saturated, shifting them from persistent synaptic strengthening, known as long-term potentiation, to persistent weakening, or long-term depression. This desensitization of synapses is an adaptive response that helps them avoid excitotoxicity...